-
公开(公告)号：US11773178B2
公开(公告)日：2023-10-03
申请号：US17588518
申请日：2022-01-31
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron Yamniuk , Mary Struthers , Stanley R. Krystek, Jr. , Akbar Nayeem , Ginger Rakestraw
IPC: C12N15/63 , C07K16/28 , A61K39/395 , A61K47/68 , C07K16/46 , A61P37/00 , A61K45/06 , A61K39/00 , C07K14/705
CPC classification number: C07K16/2878 , A61K39/3955 , A61K47/68 , A61K47/6849 , A61P37/00 , C07K16/468 , C12N15/63 , A61K45/06 , A61K47/6803 , A61K2039/505 , C07K14/70578 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/71 , C07K2317/76 , C07K2317/92
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US11254750B2
公开(公告)日：2022-02-22
申请号：US17080626
申请日：2020-10-26
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron Yamniuk , Mary Struthers , Stanley R. Krystek, Jr. , Akbar Nayeem , Ginger Rakestraw
IPC: C07K16/28 , A61K39/395 , C07K16/46 , A61P37/00 , A61K47/68 , A61K45/06 , A61K39/00 , C07K14/705
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US11261258B2
公开(公告)日：2022-03-01
申请号：US16686596
申请日：2019-11-18
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron Yamniuk , Mary Struthers , Stanley R. Krystek, Jr. , Akbar Nayeem , Ginger Rakestraw
IPC: A61K39/395 , C07K16/28 , A61K47/68 , C07K16/46 , C07K14/705 , A61K45/06 , A61K39/00
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US20240228664A9
公开(公告)日：2024-07-11
申请号：US18357007
申请日：2023-07-21
Applicant: Bristol-Myers Squibb Company
Inventor： Lin Hui Su , Ekaterina Deyanova , Burce Ergel Gurbuzbalaban , Mariana Nacht , Samantha Elaine Pace , Yun Wang , Qing Xiao , Ramakrishna Chandran , Shailesh Dudhgaonkar , Michael Louis Doyle , Michael Gilman , Richard Huang , Akbar Nayeem , Alok Sharma , Qihong Zhao
CPC classification number: C07K16/40 , A01N1/0226 , A61K45/06 , A61K47/6871 , A61K49/0002 , A61P19/02 , A61P37/06
Abstract: The present application relates to particular anti-PAD4 (peptidyl arginine deiminase 4) antibodies, nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and methods of making and using the antibodies.
-
Patent Agency Ranking
公开(公告)号：US11795231B2
公开(公告)日：2023-10-24
申请号：US17670223
申请日：2022-02-11
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron Yamniuk , Mary Struthers , Stanley R. Krystek, Jr. , Akbar Nayeem , Ginger Rakestraw
IPC: C12N15/63 , C07K16/28 , A61K39/395 , A61K47/68 , C07K16/46 , A61P37/00 , A61K45/06 , A61K39/00 , C07K14/705
CPC classification number: C07K16/2878 , A61K39/3955 , A61K47/68 , A61K47/6849 , A61P37/00 , C07K16/468 , C12N15/63 , A61K45/06 , A61K47/6803 , A61K2039/505 , C07K14/70578 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/71 , C07K2317/76 , C07K2317/92
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US20220073617A1
公开(公告)日：2022-03-10
申请号：US17258866
申请日：2019-07-10
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Xiaodi Deng , Lin Hui Su , Ginger Rakestraw , Jason R. Pinckney , David A. Critton , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova , Michael Quigley , Hadia Lemar , Akbar Nayeem
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号：US12091462B2
公开(公告)日：2024-09-17
申请号：US17258866
申请日：2019-07-10
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Xiaodi Deng , Lin Hui Su , Ginger Rakestraw , Jason R. Pinckney , David A. Critton , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova , Michael Quigley , Hadia Lemar , Akbar Nayeem
CPC classification number: C07K16/2827 , A61P35/00 , A61K2039/507 , C07K2317/34 , C07K2317/74 , C07K2317/76 , C07K2317/92
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号：US20240132622A1
公开(公告)日：2024-04-25
申请号：US18357007
申请日：2023-07-20
Applicant: Bristol-Myers Squibb Company
Inventor： Lin Hui Su , Ekaterina Deyanova , Burce Ergel Gurbuzbalaban , Mariana Nacht , Samantha Elaine Pace , Yun Wang , Qing Xiao , Ramakrishna Chandran , Shailesh Dudhgaonkar , Michael Louis Doyle , Michael Gilman , Richard Huang , Akbar Nayeem , Alok Sharma , Qihong Zhao
CPC classification number: C07K16/40 , A01N1/0226 , A61K45/06 , A61K47/6871 , A61K49/0002 , A61P19/02 , A61P37/06
Abstract: The present application relates to particular anti-PAD4 (peptidyl arginine deiminase 4) antibodies, nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and methods of making and using the antibodies.
-
公开(公告)号：US11926673B2
公开(公告)日：2024-03-12
申请号：US17579468
申请日：2022-01-19
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron Yamniuk , Mary Struthers , Stanley R. Krystek, Jr. , Akbar Nayeem , Ginger Rakestraw
IPC: A61K39/395 , A61K47/68 , A61P37/00 , C07K16/28 , C07K16/46 , C12N15/63 , A61K39/00 , A61K45/06 , C07K14/705
CPC classification number: C07K16/2878 , A61K39/3955 , A61K47/68 , A61K47/6849 , A61P37/00 , C07K16/468 , C12N15/63 , A61K2039/505 , A61K45/06 , A61K47/6803 , C07K14/70578 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/71 , C07K2317/76 , C07K2317/92
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.018 seconds)
